Please use this identifier to cite or link to this item:
|Title:||Obesity, type 2 diabetes, and testosterone in ageing men.||Austin Authors:||Wittert, Gary;Grossmann, Mathis||Affiliation:||University of Adelaide, Adelaide, Australia..
Medicine (University of Melbourne)
Freemasons Centre for Male Health and Wellbeing, South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia..
South Australian Health and Medical Research Institute North Terrace Adelaide, 5000, SA, Adelaide, Australia..
|Issue Date:||14-Jul-2022||metadata.dc.date:||2022||Publication information:||Reviews in Endocrine & Metabolic Disorders 2022; 23(6)||Abstract:||In the absence of obesity, adverse lifestyle behaviours, and use of medication such as opioids serum testosterone concentrations decrease by only a minimal amount at least until very advanced age in most men. Obesity is heterogeneous in its phenotype, and it is the accumulation of excess adipose tissue viscerally associated with insulin resistance, dyslipidaemia, inflammation, hypothalamic leptin resistance and gliosis that underpins the functional hypogonadism of obesity. Both central (hypothalamic) and peripheral mechanisms are involved resulting in a low serum total testosterone concentration, while LH and FSH are typically in the normal range. Peripherally a decrease in serum sex hormone binding globulin (SHBG) concentration only partially explains the decrease in testosterone and there is increasing evidence for direct effects in the testis. Men with obesity associated functional hypogonadism and serum testosterone concentrations below 16 nmol/L are at increased risk of incident type 2 diabetes (T2D); high testosterone concentrations are protective. The magnitude of weight loss is linearly associated with an increase in serum testosterone concentration and with the likelihood of preventing T2D or reverting newly diagnosed disease; treatment with testosterone for 2 years increases the probability of a positive outcome from a lifestyle intervention alone by approximately 40%. Whether the additional favourable benefits of testosterone treatment on muscle mass and strength and bone density and quality in the long-term remains to be determined.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/30550||DOI:||10.1007/s11154-022-09746-5||ORCID:||http://orcid.org/0000-0001-6818-6065
|Journal:||Reviews in endocrine & metabolic disorders||PubMed URL:||35834069||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/35834069/||Type:||Journal Article||Subjects:||Ageing
Type 2 diabetes
|Appears in Collections:||Journal articles|
Show full item record
checked on May 29, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.